| Phase 1/25 trials |
|
Phase 1/2
|
NCT06821503 |
Apr 2025 → Dec 2027 expected |
malignant pancreatic neoplasm |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT06825494 |
Apr 2025 → Mar 2026 overdue |
neoplasm |
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT05518045 |
Aug 2022 → Oct 2026 expected |
neoplastic disease or syndrome |
LaNova Medicines Limited |
Active not recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT05255484 |
May 2022 → Oct 2023 |
neoplasm |
LaNova Medicines Limited |
Terminated
|
No outcome recorded
|
|
Phase 1/2
|
NCT05199753 |
Mar 2022 → Dec 2024 |
neoplasm |
LaNova Medicines Limited |
Completed
|
No outcome recorded
|
| Phase 24 trials |
|
Phase 2
|
NCT06873854 |
Mar 2025 → Jan 2028 expected |
neoplastic disease or syndrome |
LaNova Medicines Limited |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06620822 |
Sep 2024 → Sep 2026 overdue |
non-small cell lung carcinoma |
Shanghai Pulmonary Hospital, Shanghai, China |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06387628 |
Jul 2024 → Apr 2026 overdue |
triple-negative breast carcinoma |
Fudan University |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06479759 |
Jan 2024 → Jun 2025 |
non-small cell lung carcinoma |
Shanghai Pulmonary Hospital, Shanghai, China |
Unknown
|
No outcome recorded
|
| Phase 31 trial |
|
Phase 3
|
NCT07362186 |
Apr 2026 → Aug 2028 expected |
gastric adenocarcinoma |
LaNova Medicines Limited |
Recruiting
|
No outcome recorded
|